[
  {
    "ts": null,
    "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
    "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
    "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768039200,
      "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
      "id": 138056039,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
      "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3"
    }
  }
]